Thymosin Alpha-1
Clinical TrialsThymosin Alpha-1
A key immune regulator derived from the thymus gland. Researched extensively for immune support, antiviral effects, and as a vaccine adjuvant.
Dose
0.8 mg to 3.2 mg
Route
SubQ injection
Cycle
4-12 weeks
Storage
Store at 2C to 8C (36F to 46F) away from light
What is Thymosin Alpha-1?
Thymosin Alpha-1 (TA1) is a naturally occurring peptide originally isolated from the thymus gland. It plays a significant role in modulating immune function, particularly by promoting the maturation and differentiation of T-cells, enhancing cytokine production (such as interferons and interleukins), and supporting overall immune response. Research protocols commonly investigate its potential in situations involving immune dysfunction, chronic infections, and as an adjuvant in certain therapeutic approaches.
Key Benefits
- Immune system enhancement
- Antiviral support
- Vaccine response improvement
- T-cell production
- Anti-inflammatory
Mechanism of Action
- Stimulates T-cell maturation
- Increases interferon levels
- Elevates interleukin levels
- Enhances humoral immunity
Best For
- Immune health research
- Viral illness research
- Longevity
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
3108.3 g/mol
Length
28 amino acids
Type
Polypeptide hormone
Amino acid sequence
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
N-terminal acetylated serine
Pharmacokinetics
Time to peak
Approximately 1-2 hours
Half-life
2 h
Time to clear
Within 24 hours
Widely reported in pharmacokinetic studies of Thymosin Alpha-1.
Research Indications
T-Cell Maturation and Differentiation
Research indicates TA1 promotes the maturation of T-lymphocytes, particularly CD4+ and CD8+ T-cells, enhancing cellular immunity.
Enhancement of Cytokine Production
Studies show TA1 can increase the production of important cytokines like interferons (IFN-α, IFN-γ) and interleukins (IL-2), which are crucial for immune signaling.
Overall Immunomodulation
Investigated for its ability to restore balance in compromised immune systems, potentially improving immune response to various challenges.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Immune System Enhancement | 1.6 mg | 2 times per week | Subcutaneous |
| Support during Chronic Viral Challenges (e.g., Hepatitis C) | 1.6 mg | 2-3 times per week | Subcutaneous |
| As a Vaccine Adjuvant | 0.8 mg to 1.6 mg | Prior to and/or concurrently with vaccination, frequency varies per study | Subcutaneous |
| Immune Support in Immunocompromised States | 1.6 mg to 3.2 mg | 2 times per week | Subcutaneous |
| Investigation for Thymic Rejuvenation | 1.6 mg | 2 times per week | Subcutaneous |
The timing and duration of administration are often adjusted based on the specific research objectives and the observed immune markers.
Peptide Interactions
- Use Caution
Immunosuppressants (e.g., corticosteroids, calcineurin inhibitors)
Thymosin Alpha-1 may counteract the effects of immunosuppressants due to its immune-enhancing properties. This combination should be monitored closely in research contexts.
- Monitor Combination
Chemotherapeutic Agents
Research has explored TA1 as an adjunct to chemotherapy, potentially mitigating immunosuppression. However, the precise interaction and timing require careful consideration and monitoring in clinical research settings.
- Synergistic
Interferon-alpha (IFN-α)
Studies suggest that TA1 and IFN-α can act synergistically to enhance antiviral and immunomodulatory effects, particularly in the context of chronic viral infections.
- Monitor Combination
Other Immune Modulators
When combined with other compounds that affect the immune system, the overall impact can be complex and requires careful observation and immune marker analysis.
- Use Caution
Live Vaccines
While TA1 is researched as a vaccine adjuvant, its use with live vaccines should be approached with caution in immunocompromised individuals, due to potential for altered immune responses.
How to Reconstitute
- 1Gather all necessary materials: vial of lyophilized Thymosin Alpha-1, bacteriostatic water for injection (BWFI), sterile syringes, and alcohol wipes.
- 2Clean the rubber stopper of the Thymosin Alpha-1 vial and the BWFI vial with alcohol wipes.
- 3Draw the desired amount of BWFI into a sterile syringe. Common reconstitution ratios aim for 1 mg/mL or 2 mg/mL.
- 4Slowly inject the BWFI into the vial containing the lyophilized Thymosin Alpha-1, directing the stream against the side of the vial to minimize foaming.
- 5Gently swirl the vial to dissolve the peptide. Do not shake vigorously.
- 6Visually inspect the solution to ensure complete dissolution and absence of particulate matter. The solution should be clear and colorless.
Aseptically reconstitute lyophilized peptide with bacteriostatic water for injection (BWFI). The final concentration can vary based on the specific research protocol.
What to Expect
- Weeks 1-4: Initial immune modulation may begin, potentially evidenced by subjective improvements in energy or well-being in some research subjects. T-cell activity might start to show measurable changes.
- Weeks 4-8: More noticeable immune system support may be observed, with potential improvements in immune response markers in laboratory settings. Subjects in research protocols may report enhanced resilience.
- Weeks 8-12: Sustained immune-modulating effects are commonly reported during this period, with potential for more robust immune responses and a better capacity to manage immune challenges.
- Post-cycle: Depending on the research goal, the benefits of immune system support may persist for some time after the cessation of administration, or a follow-up cycle may be considered.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Injection site irritation | Common | Mild |
| Mild fatigue initially | Uncommon | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.